Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: A systematic review and meta-analysis of randomized controlled trials

BMC Neurology

Volumn 10, Issue , 2010, Pages

  Skapinakis, Petros ^a,b   Bakola, Eleni ^a   Salanti, Georgia ^a   Lewis, Glyn ^b   Kyritsis, Athanasios P ^a   Mavreas, Venetsanos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALYTICAL ERROR; ARTICLE; ASTHENIA; BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; FALSE NEGATIVE RESULT; FATIGUE; HAMILTON SCALE; HUMAN; HYPOTHESIS; META ANALYSIS; METHODOLOGY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAMPLE SIZE; SOMNOLENCE; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; XEROSTOMIA; REVIEW;

DEPRESSIVE DISORDER; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 77954605044     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-10-49     Document Type: Article

References (48)

1. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008, 30:183-189.
2. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000, 69:308-312. 10.1136/jnnp.69.3.308, 1737100, 10945804.
3. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006, 25:151-157.
4. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004, 110:118-123. 10.1111/j.1600-0404.2004.00292.x, 15242420.
5. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schüpbach M, D'Ambrosia J, Thobois S, Tamma F, Herzog J, Speelman JD, Samanta J, Kubu C, Rossignol H, Poon YY, Saint-Cyr JA, Ardouin C, Moro E. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008, 131:2720-2728. 10.1093/brain/awn214, 2724899, 18941146.
6. Middleton N, Gunnell D, Whitley E, Dorling D, Frankel S. Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med 2001, 23:262-267. 10.1093/pubmed/23.4.262, 11873886.
7. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 2007, 20:161-165. 10.1177/0891988707301866, 2001165, 17712099.
8. Mamdani MM, Parikh SV, Austin PC, Upshur RE. Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000, 157:360-367. 10.1176/appi.ajp.157.3.360, 10698810.
9. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007, 22:1077-1092. 10.1002/mds.21333, 2040268, 17394234.
10. Klaassen T, Verhey FR, Sneijders GH, Rozendaal N, de Vet HC, van Praag HM. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995, 7:281-286.
11. Ghazi-Noori S, Chung TH, Deane KHO, Rickards H, Clarke CE. Therapies for depression in Parkinson's disease. The Cochrane Database of Systematic Reviews 2003, (2):CD003465. doi: 10.1002/14651858.CD003465.
12. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, Katz IR, Stern MB. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005, 20:1161-1169. 10.1002/mds.20555, 1989731, 15954137.
13. Frisina PG, Tenenbaum HR, Borod JC, Foldi NS. The effects of antidepressants in Parkinson's disease: a meta-analysis. Int J Neuroscience 2008, 118:667-682.
14. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr.Psychiatry 2003, 18:552-554. 10.1002/gps.865, 12789682.
15. Higgins JPT, Altman DG. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008) 2008, The Cochrane Collaboration, Higgins JPT, Green S., http://www.cochrane-handbook.org
16. Review Manager (RevMan) [Computer program]. 2003, Oxford, England: The Cochrane Collaboration, Version 4.2 for Windows.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 15:1539-1558.
18. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI citalopram improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacology 2002, 25:21-24.
19. Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, Canesi M, Sacilotto G, Meucci N, Mariani C, Pezzoli G. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 2006, 21:1119-1122. 10.1002/mds.20895, 16637039.
20. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B, . Depression/Parkinson Italian Study Group Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006, 253:601-607. 10.1007/s00415-006-0067-5, 16607468, Depression/Parkinson Italian Study Group.
21. Wermuth L, Sorensen PS, Timm S, Christensen B, Utzon NP, Boas J, Dupont E, Hansen E, Magnussen I, Mikkelsen B, Worm-Petersen J, Lauritzen L, Bayer L, Bech P. Depression in idiopathic Parkinson's disease treated with citalopram. A placebo-controlled trial. Nord J Psychiatry 1998, 52:163-169.
22. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destee A, Bordet R, Defebvre L. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008, 23:850-857. 10.1002/mds.21966, 18311826.
23. Serrano-Duenas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease. Rev Neurol 2002, 35:1010-1014.
24. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 2003, 23:509-513. 10.1097/01.jcp.0000088908.24613.db, 14520130.
25. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Galluci-Neto J, Barbosa ER, Valente KD, Pascual-Leone A, Marcolin MA. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75:1171-1174. 10.1136/jnnp.2003.027060, 1739189, 15258224.
26. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72:886-992. 10.1212/01.wnl.0000336340.89821.b3, 2677475, 19092112.
27. Rabey JM, Orlov E, Korczyn AD. Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease. Neurology 1996, 46:A374.
28. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Arlington, VA: American Psychiatric Publishing, Fourth, American Psychiatric Association.
29. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
30. Fahn S, Elton RL, . Members of the UPDRS Development Committee Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease 1987, 2:153-163. Florham Park, NJ: Macmillan Health Care Information, Fahn S, Marsden CD, Calne DB, Goldstein M, Members of the UPDRS Development Committee.
31. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987, 334:1-100. 10.1111/j.1600-0447.1987.tb10566.x, 2887090.
32. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002, 325:991-910. 10.1136/bmj.325.7371.991, 131022, 12411354.
33. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews 2004, 1:CD003012.
34. Martin JL, Barbanoj MJ, Schlaepfer TE, Thompson E, Perez V, Kulisevsky J. Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis. Br J Psychiatry 2003, 182:481-491.
35. Mulrow CD, Williams JW, Trivedi M, Chiquette E, Aguilar C, Cornell JE, Badgett R, Noel PH, Lawrence V, Lee S, Luther M, Ramirez G, Richardson WS, Stamm K. Treatment of depression - newer pharmacotherapies. Evid Rep Technol Assess 1999, 7:1-4.
36. Keller MB. Past, present and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003, 289:3152-3160. 10.1001/jama.289.23.3152, 12813121.
37. Grundy CT, Lambert MJ, Grundy EM. Assessing clinical significance: application to the Hamilton Rating Scale for depression. J Mental Health 1996, 5:25-33.
38. Möller HJ. Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 2001, 251(Suppl 2):II13-20.
39. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B. A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008, 18:623-627. 10.1016/j.euroneuro.2008.06.003, 18621509.
40. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5:e45. 10.1371/journal.pmed.0050045, 2253608, 18303940.
41. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002, 287:1840-1847. 10.1001/jama.287.14.1840, 11939870.
42. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008, 23:2004-2014. 10.1002/mds.22229, 18709683.
43. Marsh L, McDonald WM, Cummings J, Ravina B, . NINDS/NIMH Work Group on Depression and Parkinson's Disease Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006, 21:148-158. 10.1002/mds.20723, 16211591, NINDS/NIMH Work Group on Depression and Parkinson's Disease.
44. Neumeister A, Young T, Stastny J. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology 2004, 174:512-524. 10.1007/s00213-004-1950-3, 15249991.
45. Brooks DJ. Imaging non-dopaminergic function in Parkinson's disease. Mol Imaging Biol 2007, 9:217-222. 10.1007/s11307-007-0084-5, 17340229.
46. Frisina PG, Haroutunian V, Libow LS. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:144-148. 10.1016/j.parkreldis.2008.04.038, 18571456.
47. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008, 22:843-848. 10.1177/0269881107083808, 18308801.
48. Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord 2002, 9:125-126. 10.1016/S1353-8020(02)00011-1, 12473405.